Some new Yescarta data | GILD Message Board Posts

Gilead Sciences, Inc.

  GILD website

GILD   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  11886 of 11894  at  6/12/2019 8:45:47 AM  by


 In response to msg 11885 by  mymorningsong
view thread

Re: Some new Yescarta data

Well, I'm not wrong, and I don't think JUNO will get FDA approval. Changing the names of their drug doesn't fool the FDA. Their drug and trials are not successful in my opinion.

KITE is the commercial leader, has ironed out the CRS issues, and being first in the market means there is no need for an inferior JUNO CAR T - that is not as good (CR) and effective. FDA should not approve JUNO.

What ever happened to JUNO's CAR T? Back in Nov. 2014 JCAR015 received a breakthrough therapy designation from the FDA as a treatment for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

Here's Celgene's latest report on their CAR T from June 8, 2019. It doesn't appear to me that there has been any great advancement.

Note JUNO's MRD is only 75%. How do they expect to get FDA approval with an MRD of 75%? KITE's YESCARTA has 100% MRD.

You must think the FDA is blind to all this?

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 227
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by